Barlow PN

As seen in: Epicos.com

Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Barlow

Contact Barlow, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.

Claim your profile

Articles

Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo

May 25, 2024 |

By et al. Efficacy, Appel GB, Barlow PN, Mirzaa GM

| Epicos.com

May 25, 2024 SOURCE: PR NewsWire -- Secondary endpoint data for estimated glomerular filtration rate (eGFR) showed numerical improvement over 6 months vs.

Open in Who Shared View Duplicates (590)

See all 1 articles

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.

Claim your profile

Get in touch with Barlow

Contact Barlow, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

For PR Teams

Overview

Use Cases

Capabilities

Industries

Introducing Curation Engine

Resources

Library

Commmunity

Customers

Company

Barlow PN

Get in touch with Barlow

Actions

Is this you?

Articles

Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo

Actions

Is this you?

Get in touch with Barlow